Literature DB >> 26205746

Exenatide and Sitagliptin Decrease Interleukin 1β, Matrix Metalloproteinase 9, and Nitric Oxide Synthase 2 Gene Expression But Does Not Reduce Alveolar Bone Loss in Rats With Periodontitis.

Renata M Moraes1, Gabriela M G Lima1, Felipe E Oliveira1, Ana Carolina V Brito1, Rodrigo C Pereira1, Luciane D Oliveira1, Patrícia P Barros1, Gilson C N Franco2, Ana Lia Anbinder1.   

Abstract

BACKGROUND: New drugs for the treatment of diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4) have shown pleiotropic effects on bone metabolism and anti-inflammatory properties. The aim of this study is to evaluate the effects of exenatide (GLP-1 agonist) and sitagliptin (DPP-4 inhibitor) during periodontitis induction by ligature insertion in rats.
METHODS: Forty rats were divided into four groups: 1) animals with induced periodontitis that received exenatide (EG); 2) animals with induced periodontitis that received sitagliptin (SG); 3) animals with induced periodontitis and without drug treatment (LG); and 4) animals without induced periodontitis and without drug treatment (controls). The drugs were administered for 28 days. On the day the animals were sacrificed, blood was collected for analysis of glucose and DPP-4 levels. The gene expressions of prostaglandin-endoperoxide synthase 2, tissue inhibitor of metalloproteinase 1, Dpp4, nitric oxide synthase 2 (Nos2), interleukin 1β (Il1b), and matrix metalloproteinase 9 (Mmp9) in the gingiva; support and alveolar bone loss; connective tissue attachment; and the quantity of gingival collagen were evaluated.
RESULTS: Exenatide and sitagliptin treatments have led to a lower percentage of weight gain but did not influence glycemia. Sitagliptin reduced the serum concentration of DPP-4. Interestingly, although the gene expression profile has revealed a downregulation of Mmp9, Nos2, and Il1b in both EG and SG compared to LG, a significant protective effect was not observed on alveolar bone and collagen tissue in this model.
CONCLUSION: Regardless of the reduction of the expression of Il1b, Nos2, and Mmp9, the drugs were not effective in the stabilization or reduction of alveolar bone loss and collagen degradation in rats.

Entities:  

Keywords:  Alveolar bone loss; diabetes mellitus; dipeptidyl peptidase 4; incretins; periodontitis alveolar bone loss

Mesh:

Substances:

Year:  2015        PMID: 26205746     DOI: 10.1902/jop.2015.150278

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  5 in total

1.  [Sitagliptin inhibits lipopolysaccharide-induced inflammatory response in human gingival fibroblasts by blocking nuclear factor-κB signaling pathway].

Authors:  Xiang Liu; Wen-Yan Kang; Ling-Ling Shang; Shao-Hua Ge
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2021-04-01

2.  Nonsurgical periodontal treatment reduced aortic inflammation in ApoE(-/-) mice with periodontitis.

Authors:  Di Cui; Houxuan Li; Lang Lei; Changxing Chen; Fuhua Yan
Journal:  Springerplus       Date:  2016-06-30

3.  Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.

Authors:  Young Sil Eom; A-Ryeong Gwon; Kyung Min Kwak; Ju-Young Kim; Seung Hee Yu; Sihoon Lee; Yeun Sun Kim; Ie Byung Park; Kwang-Won Kim; Kiyoung Lee; Byung-Joon Kim
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

4.  Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis.

Authors:  Noritaka Sawada; Kei Adachi; Nobuhisa Nakamura; Megumi Miyabe; Mizuho Ito; Shuichiro Kobayashi; Shin-Ichi Miyajima; Yuki Suzuki; Takeshi Kikuchi; Makoto Mizutani; Taku Toriumi; Masaki Honda; Akio Mitani; Tatsuaki Matsubara; Keiko Naruse
Journal:  J Diabetes Res       Date:  2020-11-19       Impact factor: 4.011

Review 5.  DPP4 as a Potential Candidate in Cardiovascular Disease.

Authors:  Si-Yu Chen; Xiang-Quan Kong; Ke-Fan Zhang; Shuai Luo; Feng Wang; Jun-Jie Zhang
Journal:  J Inflamm Res       Date:  2022-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.